Roche to acquire Swiss antibody-specialist GlycArt

Roche Holding plans to buy GlycArt Biotechnology, a Swiss biotech company that specializes in enhancing the efficacy of antibodies. Roche will pay about CHF 235 million in cash for the outstanding stock of privately held GlycArt, which has three monoclonal 1 antibody drugs in preclinical trials for cancer. Monoclonal antibodies are man-made duplicates of proteins used by the immune system.

- read this story from AFX for more

PLUS: Meanwhile, Roche's first-half net profit declines as sales rise. Story

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.